Results 191 to 200 of about 892,504 (360)

ATLAS OF HAEMATOLOGY [PDF]

open access: yesJournal of Clinical Pathology, 1969
openaire   +1 more source

ATLAS "Splash event" 2008

open access: yes, 2014
"Splash events": As the LHC was being tuned up on 10 September 2008, beam was initially directed at beam collimators just outside the detector, so that a splash of particles would fill much of the detector allowing ATLAS experimenters to prepare the ...
ATLAS, Experiment
core  

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

open access: yesAdvanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao   +16 more
wiley   +1 more source

Peter Higgs autographs a LEGO model of the ATLAS detector

open access: yes, 2014
Peter Higgs autographs a LEGO model of the ATLAS ...
ATLAS, Experiment
core  

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Display of cosmic ray event going through ATLAS

open access: yes, 2014
Display of cosmic ray event going through ...
ATLAS, Experiment
core  

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang   +12 more
wiley   +1 more source

A pathology atlas of the human cancer transcriptome

open access: yesScience, 2017
M. Uhlén   +26 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy